The Biogen reversible BTK kinase inhibitor, BIIB091, is a highly selective, phase I clinical candidate for multiple sclerosis. Irreversible BTK inhibitors have been explored and developed extensively, primarily in cancer. Reversible molecules have been less common, with the most clinically advanced molecule being fenebrutinib (phase [...]
< 1 minute read
Dec. 20, 2021
BIIB091: a Reversible BTK Inhibitor
BIIB091
oral reversible BTK kinase inhibitor Ph. I candidate for multiple sclerosis from prior BTK inhibitor BIIB0685 Journal of Medicinal Chemistry Biogen